

Serena Bettoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6147497/publications.pdf>

Version: 2024-02-01

19
papers

1,072
citations

759233

12
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

1627
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
2	MYO1E Mutations and Childhood Familial Focal Segmental Glomerulosclerosis. New England Journal of Medicine, 2011, 365, 295-306.	27.0	221
3	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology, 2016, 71, 131-142.	2.2	126
4	Complement Factor B Mutations in Atypical Hemolytic Uremic Syndrome—Disease-Relevant or Benign?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2053-2065.	6.1	107
5	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
6	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. Journal of Immunology, 2017, 199, 1021-1040.	0.8	56
7	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1011-1019.	4.5	47
8	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
9	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes and Endocrinology, 2018, 6, 27-40.	11.4	24
10	C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight, 2019, 4, .	5.0	23
11	Insights into PARP Inhibitors' Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays. Journal of Biomolecular Screening, 2014, 19, 1212-1219.	2.6	17
12	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. Journal of Biological Chemistry, 2016, 291, 8214-8230a.	3.4	12
13	Nontypeable Haemophilus influenzae P5 Binds Human C4b-Binding Protein, Promoting Serum Resistance. Journal of Immunology, 2021, 207, 1566-1577.	0.8	6
14	Antibacterial Fusion Proteins Enhance Moraxella catarrhalis Killing. Frontiers in Immunology, 2020, 11, 2122.	4.8	4
15	Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics in Neisseria gonorrhoeae. Frontiers in Immunology, 2021, 12, 726801.	4.8	3
16	Clinical Isolates of Acinetobacter spp. Are Highly Serum Resistant Despite Efficient Recognition by the Complement System. Frontiers in Immunology, 2022, 13, 814193.	4.8	3
17	Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase.. Journal of Biological Chemistry, 2017, 292, 6094.	3.4	0
18	Unravelling the pathophysiology of C3G/IC-MPGN and how to predict disease progression and orient therapies. Molecular Immunology, 2017, 89, 178.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Interaction between multimeric VWF and complement: A fresh look to the pathophysiology of microvascular thrombosis. Molecular Immunology, 2017, 89, 133.	2.2	0